Table 1.
Baseline characteristics of patients retreated with tremelimumab and durvalumab
| Study population (N=17) | ||
|---|---|---|
| Sex | ||
| Male | 11 (65%) | |
| Female | 6 (35%) | |
| Median age, years | 65 (49–69) | |
| ECOG performance status | ||
| 0 | 10 (59%) | |
| 1 | 7 (41%) | |
| Histology | ||
| Epithelioid | 14 (82%) | |
| Biphasic | 3 (18%) | |
| Site | ||
| Pleural | 16 (94%) | |
| Peritoneal | 1 (6%) | |
| Previous treatments | ||
| One* | 4 (23%) | |
| Two† | 13 (77%) | |
Data are n (%), or median (IQR). ECOG=Eastern Cooperative Oncology Group.
*
First-line treatment with tremelimumab and durvalumab in the NIBIT-MESO-1 study.8
†
First line treatment with platinum plus pemetrexed; second-line treatment with tremelimumab and durvalumab in the NIBIT-MESO-1 study.